PMN — ProMIS Neurosciences Income Statement
0.000.00%
Last trade - 00:00
- $39.67m
- $37.14m
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | fx Final | fx Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.001 | 0.001 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 5.58 | 4.22 | 8.29 | 22.1 | 14.3 |
Operating Profit | -5.58 | -4.22 | -8.29 | -22.1 | -14.3 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.58 | -4.22 | -9.79 | -18.1 | -13.2 |
Net Income After Taxes | -5.58 | -4.22 | -9.79 | -18.1 | -13.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.58 | -4.22 | -9.79 | -18.1 | -13.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.58 | -4.22 | -9.79 | -18.1 | -13.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.29 | -0.887 | -1.69 | -2.58 | -1.07 |